Life expectancy at age 20 years is >20 years shorter in schizophrenia patients than the general population.
TA B L E 1
The abnormal findings are indicated in bold. The vital signs showed high-grade fever and tachycardia. The laboratory data revealed elevation of white blood cells (WBC), C-reactive protein (CRP), troponin I, creatine phosphokinase (CPK), and creatine kinase muscle and brain (CK-MB). Eosinophils were elevated later. ECG showed sinus tachycardia (ST) and nonspecific ST-T changes (ST-T). Echocardiogram revealed mild left ventricular hypertrophy (LVH) and mild pericardial effusion (PE). The ejection fraction (EF) was mildly reduced but remained within normal limits. Cardiac angiography (CAG) and cardiac magnetic resonance imaging (MRI) showed no abnormalities. showed no coronary artery obstruction or narrowing. Antibodies to coxsackievirus, echovirus, and influenza virus were negative. Chest X-ray and cardiac magnetic resonance imaging (MRI) showed no abnormalities (Table 1) .
A diagnosis of myocarditis was made, and the patient was moved to the ICU on day 18. No specific treatment was required.
Myocarditis improved rapidly after clozapine cessation, and he was returned to the psychiatric ward on day 24 and discharged from hospital on day 67. However, his auditory hallucinations and delusions were exacerbated after discharge, and he was readmitted on day 77.
After explaining the risks, benefits, and alternative therapies, the patient and his parents consented to clozapine retrial from day 89 with a gradual increase in dosage: 12.5-37.5 mg per 1-2 weeks up to 275 mg on day 220 ( Figure 1 ). Olanzapine (20 mg) and flunitrazepam (2 mg) were also administered on the day of retrial, and tapered off over 3-6 weeks. The clozapine dosage on day 240 (day of discharge) was 200 mg. After discharge, clozapine was administered at 150-300 mg, and there has been no recurrence of myocarditis for 3.5 years.
| D ISCUSS I ON
Clozapine-associated myocarditis is diagnosed by clinical findings, Systematic survey showed that 83% of cases of clozapine-induced myocarditis occurred between days 14 and 21 of treatment with the drug. 4 In our patient, myocarditis occurred on day 15.
Elevation of eosinophil count, an indicator of clozapine-associated myocarditis, tends to be delayed for ≤7 days after troponin I/T peak 3 ; eosinophil count elevation was also delayed in our patient.
Myocarditis improved after cessation of clozapine, supporting a diagnosis of clozapine-induced myocarditis.
Rapid dose titration, concomitant sodium valproate administration, and older age are risk factors for clozapine-associated myocarditis. 5 Cumulative clozapine dose >920 mg over 1-9 days doubled the risk associated with <500 mg. 5 In this case, the cumulative clozapine doses were 225 and 125 mg at first and second administrations, respectively. Neither showed rapid titration. However, Sarathy et al 6 reported a case of retrial requiring slower titration than our second trial. Slower titration may help to avoid myocarditis. Our patient's only risk factor was sodium valproate coadministration, which may inhibit clozapine metabolism. 7 Successful rechallenge was likely due to slower titration and cessation of sodium valproate.
The rate of clozapine administration in schizophrenic patients is lower in Japan (0.6%) than other developed countries (5%-30%). FUOs in patients taking clozapine are benign, myocarditis and secondary infections due to neutropenia must be excluded. 9 Life expectancy in schizophrenia patients is reduced partly because of cardiovascular diseases and suicide. 1,2 Continuous clozapine was reported to reduce the all-cause mortality rate in schizophrenia patients. 2 The patient described in this report took clozapine for 3.5 years after the retrial. The figures in previous reports were for periods of less than 3 years or were unlisted. 6, 10 Retrial of clozapine is under discussion. 10 This case suggested that even after clozapine-induced myocarditis, clozapine may be taken for a long time to improve life expectancy in schizophrenia patients.
| CON CLUS IONS
We reported a case of clozapine-induced myocarditis with successful reintroduction of clozapine. Rechallenge succeeded due to slower titration and cessation of sodium valproate. Clozapine may be taken for a long time even after clozapine-induced myocarditis to improve life expectancy in schizophrenia patients.
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